Genentech (S. San Francisco, CA) has announced disappointing phase II trial results of its anti-CD18 monoclonal antibodies in treating heart attacks. Preliminary analysis of the data in June ...

This mutation leads to the production of a defective protein called CD18, preventing leukocytes from traveling to infection sites and effectively fighting infections. Without treatment ...

Here, we tested whether this neovascularization response enhances hyperemia in a rat model of arterial insufficiency and is dependent on the recruitment of bone marrow–derived cells (BMDCs) to treated ...

The CD11b/CD18 receptor is particularly important in this process. This molecule is expressed on both neutrophils and monocytes. In common with other integrin receptors it consists of α and β subunits ...

It forms a heterodimer with CD18 to create the αMβ2 integrin (Mac-1), which is expressed on various immune cells, including macrophages. CD16 is a low-affinity Fc receptor for IgG expressed on various ...

You are free to share (copy and redistribute) this article in any medium or format within the parameters below: Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must ...

EDTA is an intravenous chelating agent with high affinity to divalent cations (lead, cadmium, and calcium) that may be beneficial in the treatment of cardiovascular disease (CVD). Although a large ...

Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.